Search

Search Constraints

You searched for: Author/Creator Rabe, Martin

Search Results

1. A preliminary account of ARIA‐E in the ongoing open‐label extension phase of BAN2401‐G000‐201 in subjects with early Alzheimer's disease: Human/Human trials: Anti‐amyloid. (7th December 2020)

2. A preliminary assessment of longitudinal amyloid status in the ongoing open‐label extension phase in subjects with early Alzheimer's disease: Human/Human trials: Anti‐amyloid. (7th December 2020)

3. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. Issue 9 (23rd March 2016)

4. AHEAD 3‐45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer's disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial): Clinical trial design and implementation. (7th December 2020)

5. AHEAD 3‐45 study: Preliminary screening and baseline characteristics from a placebo‐controlled, double‐blind study evaluating lecanemab in participants with preclinical Alzheimer's disease and elevated (A45 trial) and intermediate (A3 trial) amyloid. (31st December 2021)

7. Baseline characteristics for CLARITY AD: A phase 3 placebo‐controlled, double‐blind, parallel‐group, 18‐month study evaluating lecanemab (ban2401) in early Alzheimer's disease. (31st December 2021)